TRANSCEND-XR: 'Co-creation and implementation of an intervention to improve the understanding of TesticulaR cANcer late effects and unmet Supportive CarENeeDs of AYA survivors using eXtended Reality”
“Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study Meet uro and FICOG trial (COMBO-Seq)”
(Oncologia Medica Genitourinaria – Responsabile Struttura e Progetto 2: Dott. Giuseppe Procopio – Responsabile Progetto1: dott.ssa Patrizia Giannatempo)
Numero di Protocollo: DCE DI 7509534
Numero di posti disponibili: 1
Disciplina/Profilo: Sanitario
Tipologia: Collaborazione Professionale
Stato: Chiuso
Data Emissione:
Data Scadenza:
Expiration time: 12:00
TRANSCEND-XR: 'Co-creation and implementation of an intervention to improve the understanding of TesticulaR cANcer late effects and unmet Supportive CarENeeDs of AYA survivors using eXtended Reality”
“Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study Meet uro and FICOG trial (COMBO-Seq)”
(Oncologia Medica Genitourinaria – Responsabile Struttura e Progetto 2: Dott. Giuseppe Procopio – Responsabile Progetto1: dott.ssa Patrizia Giannatempo)
Ultimo aggiornamento: 06/11/2026